Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Operating Leases (2020 - 2025)

Foghorn Therapeutics has reported Operating Leases over the past 6 years, most recently at $40.3 million for Q4 2025.

  • Quarterly results put Operating Leases at $40.3 million for Q4 2025, up 43.77% from a year ago — trailing twelve months through Dec 2025 was $40.3 million (up 43.77% YoY), and the annual figure for FY2025 was $40.3 million, up 43.77%.
  • Operating Leases for Q4 2025 was $40.3 million at Foghorn Therapeutics, up from $15.8 million in the prior quarter.
  • Over the last five years, Operating Leases for FHTX hit a ceiling of $62.3 million in Q1 2021 and a floor of $15.8 million in Q3 2025.
  • Median Operating Leases over the past 5 years was $41.9 million (2023), compared with a mean of $41.3 million.
  • Peak annual rise in Operating Leases hit 43.77% in 2025, while the deepest fall reached 47.94% in 2025.
  • Foghorn Therapeutics' Operating Leases stood at $58.3 million in 2021, then dropped by 11.7% to $51.5 million in 2022, then fell by 12.49% to $45.1 million in 2023, then tumbled by 37.74% to $28.1 million in 2024, then skyrocketed by 43.77% to $40.3 million in 2025.
  • The last three reported values for Operating Leases were $40.3 million (Q4 2025), $15.8 million (Q3 2025), and $23.7 million (Q2 2025) per Business Quant data.